The goal of this clinical trial is to evaluate whether ¹⁸F-florbetaben PET/MR can detect systemic amyloid deposits early and noninvasively in patients with monoclonal gammopathy. The main question it aims to answer is: Can ¹⁸F-florbetaben PET/MR identify systemic amyloid deposits across clinically and histologically defined patient groups?
Participants will:
* Be screened for eligibility and asked to sign an informed consent form
* Have their vital signs measured
* Receive a single intravenous injection of approximately 300 MBq ¹⁸F-florbetaben (Neuraceq®), followed by whole-body PET/MR imaging from skull base to below the kidneys. If MRI is contraindicated (e.g., pacemaker, severe claustrophobia), PET/CT will be performed instead. The scan takes approximately one hour, during which participants lie still in the scanner
* Be monitored during and after the scan for any side effects or adverse events
* Complete study participation at the end of the imaging session (single visit, no follow-up required)

开始日期2026-10-01

申办/合作机构

University of Zurich

NCT07169630

/ Recruiting临床1期IIT

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)

Background:
About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI.
Objective:
To test whether medical imaging using a new radiotracer ([18F]PF-06445974) can measure PDE4B in the brains of people with AD or MCI.
Eligibility:
People aged 50 years and older with AD or MCI. Healthy volunteers are also needed.
Design:
Participants will have up to 5 clinic visits with 3 imaging scans of the brain.
They will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory.
Participants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each.
Participants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....

开始日期2026-07-22

申办/合作机构

National Institute of Mental Health

ACTRN12626000208303

/ Not yet recruitingN/AIIT

Finding the fibril in the haystack: A pilot study of Amyloid ([18F] Florbetaben) PET-CT in Peripheral Nerve Amyloidosis

开始日期2026-03-02

申办/合作机构

University of Sydney Union

100 项与氟[¹⁸F]贝他苯相关的临床结果

登录后查看更多信息

100 项与氟[¹⁸F]贝他苯相关的转化医学

登录后查看更多信息

100 项与氟[¹⁸F]贝他苯相关的专利（医药）

登录后查看更多信息

217

项与氟[¹⁸F]贝他苯相关的文献（医药）

2026-05-01·JPAD-Journal of Prevention of Alzheimers Disease

Discordance in amyloid positivity between visual reads and Centiloids: Impact of white matter uptake

Article

作者: Devanarayan, Viswanath ; Charil, Arnaud ; Reyderman, Larisa ; Kramer, Lynn D ; Irizarry, Michael C ; Reilhac, Anthonin ; Dhadda, Shobha ; Nelson, Todd M

BACKGROUND:

The visual interpretation of amyloid PET scans, or visual read (VR), is the most common technique used in clinical practice to identify the presence of cerebral amyloid plaques. Amyloid status (positive or negative) determined by VR or using a Centiloid (CL) cut-off shows high overall concordance. However, discordant cases can occur where the VR is positive, but the CL is below the positivity cut-off, or vice versa.

OBJECTIVES:

The objective of this analysis was to evaluate the rate of discordance and explore potential causes, particularly the role of amyloid tracer uptake in the white matter (WM), when determining amyloid status using VR and CL in screening for the elenbecestat phase 3 studies in early Alzheimer's disease (AD).

DESIGN:

Amyloid PET scans using either Florbetapir (Amyvid™), Florbetaben (Neuraceq™) or Flutemetamol (Vizamyl™) from 3,232 participants (1507 VR- and 1725 VR+) with cognitive impairment screened for the elenbecestat phase 3 studies in early AD were visually interpreted at screening by trained neuroradiologists and quantified using CL values.

SETTING:

Academic and clinical centers INTERVENTION/MEASUREMENTS: Quantitatively, amyloid positivity was defined as CL > 32.21. The number of positive cortical regions was determined by counting the number of regions with a standardized uptake value ratio (SUVr) that exceeded 1.17. PET SUVr levels in the cerebral WM were measured using an eroded WM region of interest (ROI). Statistical tests were conducted to detect differences among the four concordance groups, defined by the relationship of VR and CL status (positive or negative). Additionally, tests examined the relationship between uptake in the WM and rates and type of discordance. Receiver operating characteristic (ROC) analysis and DeLong's test were also used to examine the effect of different tracers on the discordant rates.

RESULT:

Discordance was observed in 6.53% of cases (n=211), with VR+/CL- in 4.61% (n=149) and VR-/CL+ in 1.92% (n=62). VR+/CL- discordant cases had significantly fewer amyloid-positive cortical regions compared to both VR+/CL+ and VR-/CL+ cases. VR-/CL+ cases had a significantly higher WM uptake than VR-/CL- and VR+/CL- cases. Our findings revealed a relationship between WM uptake and rates and types of discordance. High WM uptake can erroneously lead to CL+, due to gray matter (GM) contamination from the WM, and VR- status, due to reduced contrast between WM and GM, resulting in VR-/CL+ cases. Conversely, low WM uptake can result in an underestimation of CL values, inaccurately classifying a scan as CL-, and at the same time, the increased contrast may result in a VR+, thereby increasing the occurrence of discordant VR+/CL- cases.

CONCLUSION:

Variations in WM uptake significantly contribute to discordances by introducing positive or negative bias in CL values and altering the GM to WM contrast, which forms the basis of the VR. Nevertheless, the rates of discordant cases are low and VR represents a robust and validated method to determine the presence of amyloid deposition. VR enables enrolling patients with amyloid beta pathology, as seen on amyloid PET scans, whereas CL scaling was developed to provide standardized units that more consistently characterize longitudinal amyloid‑β change. These findings reflect the complementary roles of VR and CL in amyloid PET evaluation, with implications for refining diagnostic accuracy and disease monitoring in AD clinical trials and practice.

2026-05-01·JOURNAL OF NUCLEAR CARDIOLOGY

An era of precision: Emerging, research, and adjunct radiotracers for nuclear imaging of cardiac amyloidosis

Review

作者: Martin, Emily B ; Wall, Jonathan S

Cardiac amyloidosis (CA) has rapidly transitioned from an underrecognized cause of heart failure to a treatable protein-misfolding cardiomyopathy, driven by advances in transthyretin (TTR) stabilization and gene silencing, and immunotherapy to control monoclonal light chain production. Noninvasive diagnosis of transthyretin cardiac amyloidosis (ATTR) using technetium-99m bone-avid scintigraphy is now routine, yet these tracers do not bind amyloid and offer limited amyloid specificity, quantification, or monitoring of response to therapy. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) agents that directly engage amyloid or key downstream processes (fibroblast activation, inflammation, denervation) may redefine the diagnostic algorithm, phenotyping, risk stratification, and longitudinal assessment. Among these, iodine [¹²⁴I]evuzamitide (AT-01), a radioiodinated, pan-amyloid-binding peptide targeting amyloid fibrils and amyloid associated heparan sulfate proteoglycans, has emerged as the first amyloid-specific PET radiotracer to receive U.S. FDA Breakthrough Therapy designation for CA and has completed a Phase 3 pivotal evaluation. [¹⁸F]Florbetaben is similarly poised in a pivotal Phase 3 study. Herein, we summarize 1) Emerging radiotracers primed for clinical availability, including the pan-amyloid peptide tracers, [¹²⁴I]evuzamitide and [^99mTc]p5+14, the stilbene-based small molecule [¹⁸F]florbetaben, and the protein-based radiotracer, [^99mTc]aprotinin; 2) Research-focused, Aβ amyloid radiotracers and their performance in CA ([¹¹C]PiB; [¹⁸F]florbetapir, [¹⁸F]flutemetamol; and newer [¹⁸F]florbetazine); and 3) Adjunct radiotracers for exploring myocardial microenvironment ([⁶⁸Ga]FAPI, and others), emphasizing rationale for use, opportunities, synergies, strengths, limitations, and regulatory status. Finally, we outline future research and molecular targets to elucidate the pathology and the impact of novel amyloid therapeutics as they become available.

2026-03-01·Journal of Nuclear Medicine Technology

Quantitative Amyloid Brain Imaging: A Literature Review of the Centiloid Scale in Alzheimer Disease Evaluation

Review

作者: York, Benjamin ; Doroudinia, Abtin ; Colletti, Patrick M

Amyloid PET has become a pivotal imaging biomarker for Alzheimer disease (AD), enabling in vivo detection and quantification of β-amyloid deposition. However, variability in quantitative measurements across tracers, scanners, and analysis methods has considerably limited direct comparison of amyloid burden between studies and centers. To address this issue, the Centiloid Project has been developed to provide a standardized quantitative scale for amyloid PET, harmonizing results across tracers and institutions. In this literature review, we aim to summarize current evidence on the development, validation, and clinical application of the Centiloid scale in amyloid PET imaging, emphasizing its methodologic foundations, tracer-specific conversions, and diagnostic thresholds. Methods: A literature review was conducted using PubMed, Scopus, and Embase databases from January 2015 through October 2025. Search terms included "amyloid PET," "Centiloid," "SUVR," and "Alzheimer disease." We reviewed articles with quantitative amyloid PET analyses and Centiloid conversion and studies which compared multiple tracers using MIMneuro software Centiloid calibration. Results: The Centiloid method demonstrates strong intertracer and interscanner harmonization when standardized to the ¹¹C-Pittsburgh compound B reference, with high correlation (r ² > 0.9) across ¹⁸F-labeled tracers, including florbetapir, flutemetamol, and florbetaben. Most articles identified a Centiloid threshold between 20 and 25 Centiloids as indicative of significant amyloid pathology. Implementation of the Centiloid framework improved comparability across clinical trials and longitudinal studies, facilitating integration into the AT(N) research framework. Conclusion: The Centiloid scale represents a critical advancement in quantitative amyloid PET imaging, providing a universal reference that enhances data reproducibility, cross-trial comparisons, and clinical decision-making. Continued work is needed to expand standardization for novel tracers and hybrid imaging systems, ensuring full clinical translation of this metric in dementia imaging.

108

项与氟[¹⁸F]贝他苯相关的新闻（医药）

2026-07-09

·zhulinbnu

从一个连接臂（Linker）到一个诊疗平台——中美合作团队在PSMA精准核药领域取得系列原创突破

从原创分子设计到临床转化的跨学科合作导语近年来，前列腺癌精准诊疗进入"诊疗一体化（Theranostics）"时代。继PSMA-11、Pluvicto等产品相继获得FDA批准之后，全球核药研发竞争已从"有没有"进入"谁更好"的新阶段。如何进一步提高肿瘤摄取、降低正常组织辐射、改善骨转移治疗效果，并构建可持续升级的诊疗平台，成为国际核医学和放射性药物领域关注的重要科学问题。近日，由北京师范大学、北京协和医院、北京安贞医院、广州医科大学附属第一医院、福建医科大学附属第一医院及美国Five Eleven Pharma等单位合作完成的Perspective论文综述，系统总结了团队近十年来建立的O-(Carboxymethyl)-L-tyrosine（O-羧甲基-L-酪氨酸）平台技术，展示了从基础化学创新到PET显像、放射性治疗，再到多靶点诊疗一体化平台的发展历程，为国际PSMA核药研发提供了一条新的技术路线。O-(Carboxymethyl)-L-tyrosine PlatformFrom Molecular Design to Precision Theranostics 一、国际PSMA核药进入"第二代创新"时代 Ø过去十年，PSMA已经成为前列腺癌最成功的分子靶点之一。目前已有多个PSMA放射性药物获得FDA批准，包括： 68Ga-PSMA-11 18F-DCFPyL 18F-rhPSMA 177Lu-PSMA-617（Pluvicto） Ø这些药物推动了前列腺癌精准诊疗革命，也使全球PSMA市场进入数十亿美元时代。然而，第一代产品仍存在一些临床挑战：尿液放射性背景较高；部分骨盆病灶容易被膀胱遮挡；治疗药物肿瘤剂量仍有提升空间；晚期患者肿瘤异质性明显；骨转移治疗仍需进一步优化。因此，国际上开始进入第二代PSMA放射性药物研发阶段。二、一项偶然发现，开启一个全新的PSMA平台 Ø团队在PSMA配体优化过程中发现：一种新的连接臂O-(Carboxymethyl)-L-tyrosine能够明显改善PSMA配体性能。这一发现并非最初设计目标，而是在大量结构优化过程中获得的重要创新。 Ø研究发现，该连接结构能够同时改善： PSMA结合亲和力肿瘤细胞内化能力药代动力学肿瘤摄取肿瘤背景比更重要的是，它成为后续所有新一代PSMA药物共同采用的核心分子平台。三、P16-093：更清晰、更精准的PET显像 Ø基于这一平台，团队首先开发了PET显像剂：68Ga-P16-093 Ø多项临床研究证实：相比PSMA-11，P16-093具有：更高肿瘤摄取更低膀胱背景更低肾脏摄取更高病灶检出率 Ø尤其是在：前列腺原发灶生化复发患者骨盆病灶优势更加明显。对于泌尿系统附近病灶而言，降低尿液背景意味着："过去看不清的病灶，现在能够清楚显示。"这一特点对于外科术前分期和精准治疗决策具有重要意义。四、18F版本进一步提升临床推广价值 Ø为了满足大规模临床应用需求，研究团队进一步开发：18F-AlF-P16-093 Ø相比68Ga，18F具有：半衰期更长空间分辨率更高更适合中心化生产更便于全国配送临床研究显示，18F-AlF-P16-093最快可在注射后10分钟完成高质量显像，明显减少膀胱放射性干扰，为PET中心提供了新的解决方案。五、从诊断走向治疗—P17系列实现诊疗一体化 ØPET只是第一步。真正目标是：诊疗一体化（Theranostics）因此，团队利用相同平台，开发了两种177Lu治疗药物：P17-087和P17-088 Ø其中：P17-087采用DOTAGA2螯合体系，提高177Lu配位稳定性；P17-088进一步引入白蛋白结合基团，延长体内循环，提高肿瘤滞留。 Ø人体研究结果显示：两种药物均具有良好安全性； P17-087清除更快； P17-088肿瘤剂量明显提高； PSA下降率达到90%。 P17-087已有痊愈病例和7轮治疗病例（安全有效）研究提示：未来可以根据患者肾功能、骨髓储备、疾病分期，选择不同治疗方案，真正实现精准治疗。六、平台创新：一个骨架，衍生多个诊疗产品 Ø文章最大亮点，并不仅仅是几个药物，而是建立了一个可持续升级的平台。 Ø基于同一平台，研究团队进一步开发： AAZTA-093：实现68Ga和177Lu双核素标记； P17-079：增加双膦酸盐，同时靶向PSMA和骨转移； AAZTA-NI-093：加入乏氧靶向； JR11系列：针对神经内分泌分化前列腺癌。这种"模块化设计"，意味着未来可以根据不同患者、不同疾病特点，快速开发新的放射性药物。七、从基础研究到临床转化这充分体现了科研团队在放射性药物创新研发和临床转化方面不断增强的自主创新能力。八、面向未来：精准核医学进入平台化时代作者指出，未来PSMA药物的发展，将不仅局限于单一靶点，而将进一步融合：骨转移靶向乏氧靶向神经内分泌靶向 α核素治疗个体化剂量学 AI辅助精准诊疗 O-(Carboxymethyl)-L-tyrosine平台正是这一发展方向的重要代表之一。随着Ga-68、F-18、Lu-177乃至Ac-225等多种放射性核素不断加入，这一平台有望推动前列腺癌精准诊疗进入更加精准、高效、个体化的新阶段。结语从一种新的连接臂（Linker），到一系列PET显像剂；从诊断药物，到放射性治疗；从单一PSMA靶向，到多靶点诊疗平台，这项工作展示了原创分子设计驱动临床转化的完整路径。此次发表于《Journal of Medicinal Chemistry》的Perspective，不仅总结了团队近十年来在PSMA放射性药物领域的系统性创新成果，也为全球新一代精准诊疗一体化核药的发展提供了新的思路。未来，随着相关药物临床研究的持续推进，这一平台有望进一步服务于前列腺癌患者，为精准核医学的发展注入新的动力。原文：https://pubs.acs.org/doi/10.1021/acs.jmedchem.6c00960 作者团队（Authors）从原创分子设计到临床转化的跨学科合作本研究由北京师范大学、北京协和医院、北京安贞医院、广州医科大学附属第一医院、福建医科大学附属第一医院及Five Eleven Pharma（USA）共同完成，汇聚了药物化学、放射化学、核医学、临床转化和产业化等多个领域的专家： Hank F. Kung教授（通讯作者）美国宾夕法尼亚大学放射学系荣休教授（Emeritus Professor）国际著名放射性药物化学专家，从事分子影像研究四十余年，是多个经典PET显像剂的发明人，包括FDA批准的β-淀粉样蛋白PET显像剂Amyvid®（¹⁸F-florbetapir）和Neuraceq®（¹⁸F-florbetaben）。近年来主要致力于PSMA诊疗一体化、骨靶向放射性药物及新一代精准核医学平台研发。AVID 和 Five Eleven Pharma 创始人。朱霖教授（Lin Zhu）北京师范大学化学学院长期从事放射性药物化学研究，包括：PSMA精准诊疗平台，骨靶向放射性药物，肿瘤乏氧显像，阿尔茨海默病PET探针，帕金森病分子影像，新型放射性金属药物设计。在放射性药物设计与临床转化方面具有丰富经验。朱朝晖教授（Zhaohui Zhu）北京协和医院核医学科长期从事核医学临床研究、分子影像及放射性配体治疗，重点推动PSMA等新型放射性药物的临床转化，在早期临床试验、剂量学评价和监管转化方面具有丰富经验。主要作者李林璘（Linlin Li）（第一作者）赵睿玥（Ruiyue Zhao）王国昌（Guochang Wang）靳文斌（Wenbin Jin）致谢作者感谢William Eckelman博士、Karl Ploessl博士和David Alexoff先生对论文提出的宝贵建议。

2026-07-06

·BIOME生物医药展

北京亦庄举办创新生物医药路演本土药企与国际巨头共探合作

2026 行业资讯为进一步促进北京经济技术开发区（简称北京经开区，又称北京亦庄）本土创新医药企业与国际头部跨国药企之间的交流合作，近日，北京亦庄创新生物医药项目路演会举办。活动邀请9家区内创新药企进行项目路演，集中展示企业的研发成果与管线布局，并与礼来、辉瑞、阿斯利康、百时美施贵宝、拜耳等落地国际医药创新公园（BioPark）的外资药企商务和研发团队，以及中金资本、比邻星创投、亦庄国投等投资机构开展深度交流对接，共探新的合作空间，共促北京亦庄创新生物医药发展能级提升。　　本次路演会聚焦肿瘤药物、抗体药物、细胞与基因治疗等多个前沿领域，充分展现了北京经开区在生物医药领域的创新活力与最新突破。现场，加科思、康诺亚、悦康药业、先通医药等企业负责人逐个登台，围绕公司研发管线、核心技术平台等进行了详细分享，清晰呈现了公司的业务布局及未来发展潜力。　　此次路演的多个项目具有显著的技术开创性与应用价值。例如，伯汇生物自主研发的选择性FGFR4抑制诱导降解剂BB102正在开展Ⅱ期临床研究，已分别获得美国食品药品监督管理局认定的针对肝细胞癌与横纹肌肉瘤的孤儿药资格；先通医药在肿瘤、神经退行性疾病和心血管三大领域率先布局多款靶向治疗和精准诊断核药，核心产品欧韦宁®是近二十年来我国首个获得上市许可的创新型PET示踪剂，能够以无创方式对脑内β-淀粉样蛋白沉积进行可视化显像，帮助医生在阿尔茨海默病症状出现前识别潜在风险，争取早期干预的“黄金期”。　　通过搭建面对面对接机制，本次活动为创新成果落地转化奠定了扎实基础。现场，各个路演企业负责人与参会的跨国药企及投资机构代表就项目的技术亮点、最新进展等内容展开深度交流，在详细介绍各自资源及技术优势的基础上，为后续创新药物合作开发、企业投融资奠定了扎实基础。　　“随着国际医药创新公园（BioPark）建设的有序推进，越来越多的创新药企加入北京亦庄的朋友圈中。目前，国际医药创新公园已吸引礼来、辉瑞、阿斯利康、拜耳、美敦力等14家跨国药企及首药控股等一批本土创新企业集聚，逐步构建‘全球+本土’协同生态圈。”北京经开区生物技术和大健康产业局有关负责人表示，经开区将加快国际医药创新公园建设，整合政策、监管、审批等资源，吸引更多跨国药企入驻，同时搭建起本土创新药企与跨国药企的常态化对接机制，推动资源互通与优势互补，加速创新成果的转化落地，共同打造具有全球影响力的生物医药创新高地。 2026年9月16日-18日北京亦创国际会展中心 www.biome-expo.com

2026-07-02

·先通医药

先通医药1类创新核药XTR021临床试验申请获国家药监局批准

点蓝色字关注“先通医药” 先通医药欣然宣布，公司自主研发的177Lu标记、靶向PSMA的1类创新核药XTR021的临床试验申请已获国家药监局批准，用于mCRPC治疗。本次获批基于XTR021扎实的临床前药学研究和出色的临床前有效性和安全性数据。临床前研究表明，得益于创新分子设计，XTR021与177Lu-PSMA-617相比，有更高的细胞内吞和滞留能力，更好的肿瘤摄取，以显著低于177Lu-PSMA-617的剂量达到更好的肿瘤抑制效果。针对mCRPC的IIT研究阶段性数据显示，XTR021整体安全性良好，未观察到3级及以上不良事件或唾液腺毒性。有效性方面，XTR021表现出快速且积极的PSA50缓解率。基于非头对头比较数据，相比国际同类分子，现有研究数据显示XTR021或可提升疗效，且治疗相关的不良反应更具优势，凸显其具备成为下一代更优的前列腺癌放射性药物的潜力。 mCRPC：转移性去势抵抗性前列腺癌‌；PSMA：前列腺特异性膜抗原；PSA：前列腺特异性抗原联系方式投资者关系：ir@sinotau.com 商务合作：bd@sinotau.com END 关于先通医药北京先通国际医药科技股份有限公司（简称“先通医药”），始创于2005年，是中国放射性药物市场的领跑者，具备从放射性核素开发及生产、放射性药物研发、制造及商业化的全行业价值链端对端能力。先通医药秉持“做好核药，惠及大众”的使命，立足中国，放眼世界，公司总部位于北京，在上海设有研发中心，在江苏、广东、四川建设有现代化放射性药物生产基地；同时，在美国设有分支机构。以未满足的临床需求为导向，先通医药重点布局神经退行性疾病、心血管疾病、肿瘤学三大领域，建立了全面、差异化及具有协同效应的产品矩阵，于放射性诊疗一体化方面具有巨大潜力。其中，欧韦宁®为近20年来中国首个获准上市的创新性PET示踪剂；处于不同阶段的多款产品管线广泛覆盖全球放射性药物创新靶点，彰显我们管线的强大竞争力，引领创新放射性药物发展新速度。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，目的均是要指明其属前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述乃基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确定性及其他因素的影响，有些超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、中国政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本新闻稿所载前瞻性表述之任何义务；及 (b) 倘因任何前瞻性表述不能实现或变成不正确。 ▲滑动查看更多

100 项与氟[¹⁸F]贝他苯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	氟[¹⁸F]贝他苯	V09AX06	DB09148

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
阿尔茨海默症	美国	Lantheus Holdings, Inc.	2014-03-19
认知功能障碍	欧盟	Lantheus Holdings, Inc.	2014-02-20
认知功能障碍	冰岛	Lantheus Holdings, Inc.	2014-02-20
认知功能障碍	列支敦士登	Lantheus Holdings, Inc.	2014-02-20
认知功能障碍	挪威	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	欧盟	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	冰岛	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	列支敦士登	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	挪威	Lantheus Holdings, Inc.	2014-02-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
免疫球蛋白轻链淀粉样变性	临床3期	美国	Lantheus Holdings, Inc.	2023-01-13
免疫球蛋白轻链淀粉样变性	临床3期	德国	Lantheus Holdings, Inc.	2023-01-13
免疫球蛋白轻链淀粉样变性	临床3期	西班牙	Lantheus Holdings, Inc.	2023-01-13
免疫球蛋白轻链淀粉样变性	临床3期	英国	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	美国	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	德国	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	西班牙	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	英国	Lantheus Holdings, Inc.	2023-01-13
转甲状腺素蛋白淀粉样变性心肌病	临床3期	美国	Lantheus Holdings, Inc.	2023-01-13
转甲状腺素蛋白淀粉样变性心肌病	临床3期	德国	Lantheus Holdings, Inc.	2023-01-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03706261 (CTgov)	临床1期	阿尔茨海默症	145	18F-Florbetaben+18F-MK-6240	糧築繭夢製鏇鑰艱蓋範(壓廠襯襯簾鬱遞鹽觸製) = 憲憲夢襯窪艱窪醖壓憲鑰壓膚衊鬱顧齋範壓鏇 (顧糧襯鏇壓鬱醖網餘醖, 0.23) 更多	-	2025-08-01
NCT02831283 (CTgov)	临床2期	阿尔茨海默症 \| 炎症	60	11C-PBR28+18F-Florbetaben (Amyloid-positive With Cognitive Impairment (AD))	簾鏇簾壓糧構淵遞鹽網(遞獵顧膚築窪鏇繭選鏇) = 壓築鏇窪齋構獵鏇餘淵鹹餘醖衊製衊顧獵構鹹 (願憲廠糧淵壓築簾廠窪, 0.18) 更多	-	2025-03-05
				11C-PBR28+18F-Florbetaben (Amyloid-positive Without Impairment (Preclinical AD))	簾鏇簾壓糧構淵遞鹽網(遞獵顧膚築窪鏇繭選鏇) = 艱餘網願範顧淵壓鑰繭鹹餘醖衊製衊顧獵構鹹 (願憲廠糧淵壓築簾廠窪, 0.16) 更多
NCT01222351 (CTgov)	N/A	阿尔茨海默症 \| 认知功能障碍	161	BAY 94-9172 (Florbetaben)	窪壓膚網夢繭壓襯醖選 = 衊衊壓積醖選餘衊願糧鑰壓醖範艱憲鹹範願製 (鑰構衊網餘廠艱選憲醖, 壓膚遞糧窪觸簾網構憲 ~ 鑰淵築窪鏇網願製積齋) 更多	-	2024-05-06
NCT03744312 (CTgov)	临床1/2期	阿尔茨海默症 \| 炎症	9	Florbetaben+11C-ER176 (Cognitive Impairment)	廠鑰齋構鹽鏇鬱廠餘糧(壓鹹糧範築鬱遞壓鑰製) = 獵鹽鏇醖齋憲積製襯鏇襯襯鹽鹹願衊遞夢壓觸 (艱衊窪構構糧憲淵製鹹, 觸艱鹹艱獵衊艱繭鹹壓 ~ 顧獵顧繭網選鏇獵獵簾) 更多	-	2023-09-13
				Florbetaben+11C-ER176 (No Cognitive Impairment)	廠鑰齋構鹽鏇鬱廠餘糧(壓鹹糧範築鬱遞壓鑰製) = 鹽餘艱遞獵餘齋範遞餘襯襯鹽鹹願衊遞夢壓觸 (艱衊窪構構糧憲淵製鹹, 襯淵構鏇觸鑰糧憲構衊 ~ 壓築蓋蓋鹽獵網範壓衊) 更多
NCT02681172 (CTgov)	临床4期	阿尔茨海默症	218	florbetaben	鹹憲積壓選獵衊糧壓積 = 艱顧淵製廠鏇鏇窪艱製鹹願鑰壓簾淵襯範顧膚 (齋製觸顧蓋鏇膚憲範廠, 壓築蓋壓觸膚淵觸蓋鏇 ~ 膚夢製艱餘構窪餘壓鏇) 更多	-	2018-11-02
NCT02681172 (AAIC2017)	临床4期	轻度痴呆	205	Florbetaben PET imaging	願遞衊窪遞構淵獵顧鏇(構獵構繭廠糧窪獵鏇壓) = 醖獵鹹糧繭積壓顧願積構鏇鏇製壓鑰衊鬱鏇窪 (蓋鏇壓遞積壓鏇淵艱襯, 59.9 ~ 73.2) 更多	-	2017-07-01
NCT01020838 (Pubmed \| J Nucl Med)	临床3期	阿尔茨海默症 \| 脑淀粉样血管病	82	18F-Florbetaben (In-person-trained interpreters)	積醖齋顧繭鬱鹹觸艱鹽(淵蓋鏇餘製簾觸鏇獵夢) = 齋遞鏇夢選網鏇餘遞積膚衊顧廠廠鬱簾網鏇膚 (鬱築蓋製夢繭壓齋壓艱 ) 更多	-	2016-06-01
				18F-Florbetaben (Electronic training method)	積醖齋顧繭鬱鹹觸艱鹽(淵蓋鏇餘製簾觸鏇獵夢) = 淵範衊鹽構艱製蓋顧衊膚衊顧廠廠鬱簾網鏇膚 (鬱築蓋製夢繭壓齋壓艱 ) 更多
NCT01020838 (Pubmed \| Alzheimers Dement)	临床3期	阿尔茨海默症 β-amyloid-positive	216	Florbetaben PET imaging	顧齋醖簾鏇鬱衊壓鑰廠(遞膚鑰範顧窪窪衊製餘) = 網簾壓製蓋構襯齋膚願製願範窪齋鏇鬱糧壓鹽 (繭顧製獵簾簾壓淵鹹窪, 93.8 ~ 100) 更多	-	2015-08-01
NCT01138111 (Pubmed \| J Neurol Neurosurg Psychiatry)	临床1期	阿尔茨海默症	45	18F-florbetaben (FBB+)	襯蓋餘淵觸衊積鑰遞鹹(窪願壓醖膚顧鹽積壓獵) = 糧築齋鑰築淵鬱願衊鏇願顧選選觸鹽獵顧鹽構 (壓製糧艱選鬱夢淵蓋襯 ) 更多	-	2015-04-01
				18F-florbetaben (FBB-)	積鑰願鬱醖願鬱糧鏇廠(簾鏇糧壓淵壓夢憲製鑰) = 窪齋餘鑰膚淵簾襯鑰鹹遞蓋鹽顧蓋鹽獵顧簾鑰 (壓積鹹鹽選遞構繭壓鏇 )
AAIC2013	N/A	阿尔茨海默症	-	florbetaben (AD patients)	網膚齋顧衊醖製齋醖構(廠衊壓鏇壓製繭醖淵憲) = 艱網艱願繭積鏇廠遞鹹廠餘鏇築襯網製獵遞構 (鏇製襯衊鹽壓夢醖顧鹽, 0.77 ~ 0.86) 更多	-	2013-07-01
				florbetaben (Healthy volunteers)	蓋製醖遞醖醖齋鬱齋艱(選鏇鹹遞醖鑰齋鬱衊壓) = 艱獵壓範願遞獵簾襯選顧鬱艱夢淵範積齋觸襯 (齋願夢齋膚淵願簾簾獵, 73.9 ~ 88.2)